The share price of Esperion Therapeutics ESPR lost 54.3% on Mar 16 after management reported a disagreement with one of its partners over certain milestone payments.
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Invite this member to nests
Message this member
Add this member as a connection
Please note:
This action will also remove this member from your connections and send a report to the site admin.
Please allow a few minutes for this process to complete.
Responses